EP2266946A3 - Composé pour le traitement des troubles métaboliques - Google Patents

Composé pour le traitement des troubles métaboliques Download PDF

Info

Publication number
EP2266946A3
EP2266946A3 EP10184293A EP10184293A EP2266946A3 EP 2266946 A3 EP2266946 A3 EP 2266946A3 EP 10184293 A EP10184293 A EP 10184293A EP 10184293 A EP10184293 A EP 10184293A EP 2266946 A3 EP2266946 A3 EP 2266946A3
Authority
EP
European Patent Office
Prior art keywords
carbon atoms
ring
alkyl
compound
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10184293A
Other languages
German (de)
English (en)
Other versions
EP2266946A2 (fr
Inventor
Kirvin Hodge
Albert Lee
Shalini Sharma
Reid Von Borstel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellstat Therapeutics Corp
Original Assignee
Wellstat Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Therapeutics Corp filed Critical Wellstat Therapeutics Corp
Publication of EP2266946A2 publication Critical patent/EP2266946A2/fr
Publication of EP2266946A3 publication Critical patent/EP2266946A3/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C07C69/92—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP10184293A 2003-02-13 2004-02-09 Composé pour le traitement des troubles métaboliques Withdrawn EP2266946A3 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44716803P 2003-02-13 2003-02-13
EP04709467.7A EP1601251B1 (fr) 2003-02-13 2004-02-09 Composes pour le traitement de troubles metaboliques

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP04709467.7A Division-Into EP1601251B1 (fr) 2003-02-13 2004-02-09 Composes pour le traitement de troubles metaboliques
EP04709467.7 Division 2004-02-09

Publications (2)

Publication Number Publication Date
EP2266946A2 EP2266946A2 (fr) 2010-12-29
EP2266946A3 true EP2266946A3 (fr) 2012-12-12

Family

ID=32908414

Family Applications (2)

Application Number Title Priority Date Filing Date
EP04709467.7A Expired - Lifetime EP1601251B1 (fr) 2003-02-13 2004-02-09 Composes pour le traitement de troubles metaboliques
EP10184293A Withdrawn EP2266946A3 (fr) 2003-02-13 2004-02-09 Composé pour le traitement des troubles métaboliques

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP04709467.7A Expired - Lifetime EP1601251B1 (fr) 2003-02-13 2004-02-09 Composes pour le traitement de troubles metaboliques

Country Status (19)

Country Link
US (3) US7615575B2 (fr)
EP (2) EP1601251B1 (fr)
JP (2) JP4697962B2 (fr)
KR (1) KR101106631B1 (fr)
CN (1) CN1750758B (fr)
AU (2) AU2004212905B2 (fr)
BR (1) BRPI0407506A (fr)
CA (1) CA2513092C (fr)
ES (1) ES2530235T3 (fr)
HK (1) HK1079400A1 (fr)
IL (1) IL169332A (fr)
MX (1) MXPA05008600A (fr)
NO (1) NO334606B1 (fr)
NZ (1) NZ542072A (fr)
PL (1) PL377712A1 (fr)
RU (2) RU2005128501A (fr)
UA (1) UA81013C2 (fr)
WO (1) WO2004073611A2 (fr)
ZA (1) ZA200504558B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL159320A0 (en) * 2001-06-12 2004-06-01 Wellstat Therapeutics Corp Compounds for the treatment of metabolic disorders
JP2006507303A (ja) * 2002-11-01 2006-03-02 ウェルスタット セラピューティクス コーポレイション 代謝障害の処置のための化合物
US7615575B2 (en) * 2003-02-13 2009-11-10 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
WO2004091486A2 (fr) * 2003-04-15 2004-10-28 Wellstat Therapeutics Corporation Composes destines au traitement de troubles metaboliques
WO2004093806A2 (fr) * 2003-04-22 2004-11-04 Wellstat Therapeutics Corporation Composes pour le traitement de troubles metaboliques
ATE526018T1 (de) * 2003-04-30 2011-10-15 Wellstat Therapeutics Corp Verbindungen zur behandlung von stoffwechselstörungen
US7906675B2 (en) * 2003-08-20 2011-03-15 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
CA2602854C (fr) * 2005-04-01 2013-05-14 Wellstat Therapeutics Corporation Composes pour le traitement de troubles metaboliques
UA95613C2 (ru) * 2005-11-09 2011-08-25 Уеллстат Терепьютикс Корпорейшн Соединения для лечения расстройсв метаболизма
EP1976377A4 (fr) * 2006-01-25 2010-06-23 Wellstat Therapeutics Corp Composés destinés au traitement des troubles du métabolisme
AU2007208127A1 (en) * 2006-01-25 2007-08-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
CA2637373A1 (fr) * 2006-01-25 2007-08-02 Wellstat Therapeutics Corporation Composes destines au traitement des troubles du metabolisme
WO2007092729A2 (fr) 2006-02-02 2007-08-16 Wellstat Therapeutics Corporation Composes pour le traitement de troubles metaboliques
WO2007095462A2 (fr) 2006-02-13 2007-08-23 Wellstat Therapeutics Corporation Composes pour le traitement de troubles du metabolisme
MX2008011022A (es) * 2006-02-28 2008-09-10 Wellstat Therapeutics Corp Compuestos para el tratamiento de trastornos metabolicos.
CA2647258A1 (fr) * 2006-03-31 2007-10-18 Wellstat Therapeutics Corporation Traitement de combinaison de troubles metaboliques
MX2008014560A (es) * 2006-05-18 2008-11-28 Wellstat Therapeutics Corp Compuestos para el tratamiento de trastornos metabolicos.
AU2007257854B2 (en) * 2006-06-09 2012-04-12 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
AU2007285827A1 (en) * 2006-08-17 2008-02-21 Wellstat Therapeutics Corporation Combination treatment for metabolic disorders
FR2917084B1 (fr) * 2007-06-05 2009-07-17 Galderma Res & Dev Nouveaux derives d'acide 3-phenyl propanoique activateurs des recpteurs de type ppar, leur methode de preparation et leur utilisation dans des compositions cosmetiques ou pharmaceutiques.
US8481595B2 (en) * 2008-01-15 2013-07-09 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
AU2013200226B2 (en) * 2008-03-13 2015-01-15 Wellstat Therapeutics Corporation Compounds and method for reducing uric acid
UA103894C2 (ru) * 2008-03-13 2013-12-10 Уеллстат Терепьютикс Корпорейшн Соединения и способ для снижения уровня мочевой кислоты
WO2011046800A1 (fr) * 2009-10-13 2011-04-21 Wellstat Therapeutics Corporation Composés 3-substitués pour réduire l'acide urique
US20130331452A1 (en) 2010-09-08 2013-12-12 Wellstat Therapeutics Corporation Benzoic acid compounds for reducing uric acid
CN102399148B (zh) * 2010-09-14 2014-03-05 中国科学院成都生物研究所 一类降血脂化合物及其制备方法和用途
FR2976943B1 (fr) * 2011-06-23 2013-07-12 Metabolys Derives de piperazine, leurs procedes de preparation et leurs utilisations dans le traitement de l'insulinoresistance
RU2723486C2 (ru) * 2014-10-10 2020-06-11 Прометик Фарма Смт Лимитед Замещенные ароматические соединения и фармацевтические композиции для предотвращения и лечения диабета
US10702488B2 (en) * 2017-12-19 2020-07-07 Theriac Biomedical Inc. PPAR-γ activators, HDAC inhibitors and their therapeutical usages
US11497723B1 (en) * 2017-12-19 2022-11-15 Tony Antakly PPAR-gamma activators, HDAC inhibitors and their therapeutical usages
SG11202103011YA (en) * 2018-10-11 2021-04-29 Basf As Aromatic compounds and pharmaceutical uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1393854A (en) * 1973-02-26 1975-05-14 Pfizer Benzoic acid compounds and pharmaceutical compositions containing them
WO1999011255A1 (fr) * 1997-08-28 1999-03-11 Ono Pharmaceutical Co., Ltd. Regulateurs du recepteur active par les agents de proliferation des peroxysomes
WO2002100341A2 (fr) * 2001-06-12 2002-12-19 Wellstat Therapeutics Corporation Composes destines au traitement de troubles metaboliques

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2100341A (en) * 1934-11-24 1937-11-30 United Shoe Machinery Corp Shoe bottom coating machine
US4098816A (en) * 1973-08-23 1978-07-04 Beecham Group Limited Polycyclic oxy-aromatic acid
CA1041541A (fr) * 1974-01-14 1978-10-31 Giorgio Pifferi Sels de l'acide cyclopropyl-4 methyleneoxy-3 chlorophenylacetique
CS175831B1 (fr) 1974-12-17 1977-05-31
GB1561350A (en) 1976-11-05 1980-02-20 May & Baker Ltd Benzamide derivatives
DE2962737D1 (en) * 1978-11-14 1982-06-24 Sagami Chem Res Process for the preparation of aromatically substituted acetic acids
WO1985003701A1 (fr) 1984-02-14 1985-08-29 Hidefumi Hirai PROCEDE DE PREPARATION DE DERIVES DE PHENOL p-SUBSTITUE
DE3884825D1 (de) 1987-02-16 1993-11-18 Konishiroku Photo Ind Entwickler für lichtempfindliche lithographische Druckplatte, gemeinschaftlich verarbeitungsfähig für den Negativ-Typ und den Positiv-Typ und Entwicklerzusammensetzung für lichtempfindliches Material.
JPH0770025B2 (ja) 1987-09-16 1995-07-31 富士通株式会社 薄膜磁気ヘッドの製造方法
US4923501A (en) 1987-11-04 1990-05-08 Kumiai Chemical Industry Co., Ltd. Pyrimidine derivatives, processes for their production, and herbicidal method and compositions
DE3738406A1 (de) * 1987-11-12 1989-05-24 Henkel Kgaa Sebosuppressive topische zubereitungen
JPH01216961A (ja) 1988-02-25 1989-08-30 Takeda Chem Ind Ltd １２−リポキシゲネース阻害剤
GB8806471D0 (en) * 1988-03-18 1988-04-20 Tisdale M J Biologically active material characterised by catabolic activity generally associated with cachexia inducing tumours
US4897397A (en) * 1988-12-16 1990-01-30 Schering Corporation Aryl-alkynoic, alkenoic or alkanoic compounds and compositions useful as antiallergy and anti-inflammatory agents
JPH0348603A (ja) 1989-07-14 1991-03-01 Wakayama Pref Gov 抗菌防臭材料
HUT60458A (en) 1991-02-01 1992-09-28 Sandoz Ag Process for producing benzyloxyphenyl derivatives and pharmaceutical compositions comprising same
US5589492A (en) * 1992-04-10 1996-12-31 Smithkline Beecham Plc Heterocyclic compounds and their use in the treatment of Type-II diabetes
KR950703280A (ko) * 1992-09-09 1995-09-20 미리암 디.메코너헤이 제초성 벤젠 화합물(Herbicidal Benzene Compounds)
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
JPH06293700A (ja) 1993-04-08 1994-10-21 Nippon Soda Co Ltd ６−クロロサリチル酸の製造法
GB9315595D0 (en) 1993-07-28 1993-09-08 Res Inst Medicine Chem New compounds
JPH07206658A (ja) 1994-01-12 1995-08-08 Shiseido Co Ltd 尋常性座瘡治療剤
GB9401460D0 (en) 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
JPH08119959A (ja) 1994-10-20 1996-05-14 Oyo Seikagaku Kenkyusho キサントン誘導体及びこれを有効成分とするモノアミン酸化酵素阻害剤
US5728718A (en) 1994-12-20 1998-03-17 The United States Of America As Represented By The Department Of Health And Human Services 2,5-diamino-3,4-disubstituted-1,6-diphenylhexane isosteres comprising benzamide, sulfonamide and anthranilamide subunits and methods of using same
US5530157A (en) 1995-02-16 1996-06-25 Scios Nova Inc. Anti-inflammatory benzoic acid derivatives
FR2730731B1 (fr) 1995-02-20 1997-04-04 Rhone Poulenc Chimie Procede de carboxylation d'un ether aromatique
WO1996028423A1 (fr) 1995-03-15 1996-09-19 Sankyo Company, Limited Composes dipeptidiques de structure ahpba
JPH08325250A (ja) 1995-05-31 1996-12-10 Sumitomo Metal Ind Ltd 新規置換フェノール誘導体
US5519133A (en) 1995-06-02 1996-05-21 American Cyanamid Co. 3-(3-aryloxyphenyl)-1-(substituted methyl)-s-triazine-2,4,6-oxo or thiotrione herbicidal agents
US6194406B1 (en) 1995-12-20 2001-02-27 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic disease
US6423704B2 (en) 1995-12-20 2002-07-23 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases
WO1997025992A1 (fr) 1996-01-16 1997-07-24 Merck & Co., Inc. Antagonistes des recepteurs de l'oxytocine tocolytique
NZ332789A (en) 1996-05-24 2000-05-26 Neurosearch As Phenyl derivatives containing an acidic group, their preparation and their use as chloride channel blockers
DE69736642T2 (de) 1996-07-19 2007-09-20 Takeda Pharmaceutical Co. Ltd. Heterocyclische Verbindungen, ihre Herstellung und Verwendung
JP2001500864A (ja) * 1996-09-13 2001-01-23 メルク エンド カンパニー インコーポレーテッド トロンビン阻害物質
JPH1087489A (ja) 1996-09-13 1998-04-07 Sankyo Co Ltd Ａｈｐｂａ構造含有ジペプチド化合物を有効成分とする医薬
JP3981771B2 (ja) 1996-10-19 2007-09-26 株式会社クレハ ２−ベンジルオキシ−６−アルコキシ安息香酸誘導体、その製造方法及び、農園芸用殺菌剤
JP2003517427A (ja) 1997-09-09 2003-05-27 メルク エンド カムパニー インコーポレーテッド ３−（ヨードフェノキシメチル）カルバペネム系抗菌剤
KR20010015639A (ko) 1997-09-30 2001-02-26 스즈키 다다시 술포닐 유도체
AU735737B2 (en) 1997-10-14 2001-07-12 Asahi Kasei Kabushiki Kaisha Biphenyl-5-alkanoic acid derivatives and use thereof
US6384080B1 (en) * 1998-04-20 2002-05-07 Fujisawa Pharmaceutical Co., Ltd. Anthranilic acid derivatives as inhibitors of the cGMP-phosphodiesterase
JP4154773B2 (ja) 1998-11-13 2008-09-24 住友電気工業株式会社 単結晶製造方法および装置
GB9914371D0 (en) 1999-06-18 1999-08-18 Smithkline Beecham Plc Novel compounds
CA2325358C (fr) 1999-11-10 2005-08-02 Pfizer Products Inc. Amides de l'acide 7-¬(4'-trifluoromethylbiphenyl-2-carbonyl)amino|-quinoleine-3-carboxylique et methodes pour inhiber la secretion d'apolipoproteine b
US6677473B1 (en) * 1999-11-19 2004-01-13 Corvas International Inc Plasminogen activator inhibitor antagonists
AUPQ570100A0 (en) * 2000-02-17 2000-03-09 Fujisawa Pharmaceutical Co., Ltd. Beta-alanine derivatives and their use as receptor antagonists
US6632765B1 (en) 2000-06-23 2003-10-14 Chervon U.S.A. Inc. Catalyst regeneration via reduction with hydrogen
JP4515026B2 (ja) 2000-06-28 2010-07-28 アムジェン インコーポレイテッド キノリニルおよびベンゾチアゾリルｐｐａｒ−ガンマ調節剤
WO2002002101A1 (fr) 2000-07-05 2002-01-10 Ajinomoto Co., Inc. Composes hypoglycemiques
UY26911A1 (es) 2000-08-29 2002-03-22 Abbott Lab Ácidos amino (oxo) acéticos inhibidores de la proteina tirosina fosfatasa
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
DE10135027A1 (de) * 2001-07-18 2003-02-06 Solvay Pharm Gmbh Verwendung Trifluoracetylalkyl-substituierter Phenyl-, Phenol- und Benzoylderivate in der Behandlung und/oder Prophylaxe von Obestias und deren Begleit- und/oder Folgeerkrankungen
PT1477472E (pt) * 2002-02-21 2009-03-17 Asahi Kasei Pharma Corp Derivado de ácido fenilalcanóico substituído e sua utilização
JP2006507303A (ja) * 2002-11-01 2006-03-02 ウェルスタット セラピューティクス コーポレイション 代謝障害の処置のための化合物
DE10257785A1 (de) * 2002-12-11 2004-07-01 Bayer Healthcare Ag Isophthalsäurederivate
EP1593667A4 (fr) * 2003-02-12 2009-03-04 Takeda Pharmaceutical Derive d'amine
US7615575B2 (en) 2003-02-13 2009-11-10 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
JP4282345B2 (ja) 2003-03-12 2009-06-17 株式会社日立製作所 半導体集積回路装置
WO2004091486A2 (fr) * 2003-04-15 2004-10-28 Wellstat Therapeutics Corporation Composes destines au traitement de troubles metaboliques
WO2004093806A2 (fr) * 2003-04-22 2004-11-04 Wellstat Therapeutics Corporation Composes pour le traitement de troubles metaboliques
ATE526018T1 (de) * 2003-04-30 2011-10-15 Wellstat Therapeutics Corp Verbindungen zur behandlung von stoffwechselstörungen
US7470807B2 (en) * 2003-08-14 2008-12-30 Asahi Kasei Pharma Corporation Substituted arylalkanoic acid derivatives and use thereof
US7906675B2 (en) 2003-08-20 2011-03-15 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
JP2007502815A (ja) 2003-08-20 2007-02-15 イーライ リリー アンド カンパニー Ｐｐａｒ調節因子
WO2005064018A2 (fr) * 2003-12-22 2005-07-14 Ventana Medical Systems, Inc. Synthese assistee par micro-onde d'echantillons d'acide nucleique
CA2602854C (fr) * 2005-04-01 2013-05-14 Wellstat Therapeutics Corporation Composes pour le traitement de troubles metaboliques
UA95613C2 (ru) * 2005-11-09 2011-08-25 Уеллстат Терепьютикс Корпорейшн Соединения для лечения расстройсв метаболизма
EP1976377A4 (fr) * 2006-01-25 2010-06-23 Wellstat Therapeutics Corp Composés destinés au traitement des troubles du métabolisme
CA2637373A1 (fr) * 2006-01-25 2007-08-02 Wellstat Therapeutics Corporation Composes destines au traitement des troubles du metabolisme
AU2007208127A1 (en) * 2006-01-25 2007-08-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
WO2007092729A2 (fr) * 2006-02-02 2007-08-16 Wellstat Therapeutics Corporation Composes pour le traitement de troubles metaboliques
WO2007095462A2 (fr) * 2006-02-13 2007-08-23 Wellstat Therapeutics Corporation Composes pour le traitement de troubles du metabolisme
MX2008014560A (es) * 2006-05-18 2008-11-28 Wellstat Therapeutics Corp Compuestos para el tratamiento de trastornos metabolicos.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1393854A (en) * 1973-02-26 1975-05-14 Pfizer Benzoic acid compounds and pharmaceutical compositions containing them
WO1999011255A1 (fr) * 1997-08-28 1999-03-11 Ono Pharmaceutical Co., Ltd. Regulateurs du recepteur active par les agents de proliferation des peroxysomes
WO2002100341A2 (fr) * 2001-06-12 2002-12-19 Wellstat Therapeutics Corporation Composes destines au traitement de troubles metaboliques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HALL J H ET AL: "Hypolipidemic activity in rodents of phenobarbital and related derivatives", ARCHIV DER PHARMAZIE, WILEY - VCH VERLAG GMBH & CO. KGAA, DE, vol. 323, no. 9, 1 January 1990 (1990-01-01), pages 579 - 586, XP008087557, ISSN: 0365-6233, DOI: 10.1002/ARDP.19903230905 *

Also Published As

Publication number Publication date
NO20053211L (no) 2005-10-20
CA2513092A1 (fr) 2004-09-02
NO20053211D0 (no) 2005-06-30
RU2005128501A (ru) 2006-04-27
US20080015254A1 (en) 2008-01-17
HK1079400A1 (en) 2006-04-07
NO334606B1 (no) 2014-04-22
IL169332A0 (en) 2007-07-04
KR20050098924A (ko) 2005-10-12
KR101106631B1 (ko) 2012-01-20
RU2521284C2 (ru) 2014-06-27
AU2004212905A1 (en) 2004-09-02
AU2004212905B2 (en) 2008-10-09
CA2513092C (fr) 2011-11-01
AU2008229824A1 (en) 2008-10-30
EP2266946A2 (fr) 2010-12-29
CN1750758A (zh) 2006-03-22
JP2006517920A (ja) 2006-08-03
BRPI0407506A (pt) 2006-02-14
WO2004073611A3 (fr) 2004-11-25
US7615575B2 (en) 2009-11-10
IL169332A (en) 2011-04-28
US20060247309A1 (en) 2006-11-02
NZ542072A (en) 2007-11-30
US7932290B2 (en) 2011-04-26
EP1601251B1 (fr) 2014-11-12
EP1601251A4 (fr) 2007-03-28
ES2530235T3 (es) 2015-02-27
JP4697962B2 (ja) 2011-06-08
UA81013C2 (en) 2007-11-26
WO2004073611A2 (fr) 2004-09-02
ZA200504558B (en) 2010-04-28
RU2008151414A (ru) 2010-06-27
US20100087541A1 (en) 2010-04-08
US7605181B2 (en) 2009-10-20
CN1750758B (zh) 2012-06-20
MXPA05008600A (es) 2005-11-04
PL377712A1 (pl) 2006-02-06
JP2009242434A (ja) 2009-10-22
EP1601251A2 (fr) 2005-12-07

Similar Documents

Publication Publication Date Title
EP2266946A3 (fr) Composé pour le traitement des troubles métaboliques
HK1083462A1 (en) Compounds for the treatment of metabolic disorders
HK1083460A1 (en) Compounds for the treatment of metabolic disorders
HK1084026A1 (en) Compounds for the treatment of metabolic disorders
UA95613C2 (ru) Соединения для лечения расстройсв метаболизма
ZA200806444B (en) Compounds for the treatment of metabolic disorders
WO2007095462A3 (fr) Composes pour le traitement de troubles du metabolisme
WO2007087505A3 (fr) Composés destinés au traitement des troubles du métabolisme
WO2007137008A3 (fr) Composés pour le traitement de troubles métaboliques
WO2006127133B1 (fr) Composes pour le traitement de troubles metaboliques
UA88772C2 (ru) Соединения для лечения расстройств метаболизма
WO2007117791A3 (fr) Traitement de combinaison de troubles metaboliques
WO2007087506A3 (fr) Composés destinés au traitement des troubles du métabolisme
WO2007087504A3 (fr) Composés destinés au traitement des troubles du métabolisme
WO2007092729A3 (fr) Composes pour le traitement de troubles metaboliques

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 1601251

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1150828

Country of ref document: HK

RIC1 Information provided on ipc code assigned before grant

Ipc: C07C 59/64 20060101ALI20120828BHEP

Ipc: A61K 31/24 20060101ALI20120828BHEP

Ipc: A61K 31/192 20060101ALI20120828BHEP

Ipc: A61P 3/10 20060101ALI20120828BHEP

Ipc: C07C 69/734 20060101AFI20120828BHEP

Ipc: C07C 65/24 20060101ALI20120828BHEP

Ipc: C07C 59/68 20060101ALI20120828BHEP

Ipc: A61P 3/00 20060101ALI20120828BHEP

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/24 20060101ALI20121108BHEP

Ipc: A61P 3/00 20060101ALI20121108BHEP

Ipc: A61K 31/192 20060101ALI20121108BHEP

Ipc: C07C 59/64 20060101ALI20121108BHEP

Ipc: A61P 3/10 20060101ALI20121108BHEP

Ipc: C07C 69/734 20060101AFI20121108BHEP

Ipc: C07C 59/68 20060101ALI20121108BHEP

Ipc: C07C 69/92 20060101ALI20121108BHEP

Ipc: C07C 69/76 20060101ALI20121108BHEP

Ipc: C07C 65/24 20060101ALI20121108BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130613

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1150828

Country of ref document: HK